IIFL View
Go
  • Dr Lal Pathlabs

    We estimate revenue/PAT CAGR of 16.3%/19.7% respectively over FY18-20E. We are positive on DLPL due to (a) positive industry macros, (b) business expansion in east, south and west, (c) ramping up of its wellness business under brand Swasth and (d) better Ro...

    Accumulate Reco. Price: 900.00

  • Dr Reddy's Labs

    DRL is facing patent litigation in the US court after at risk launch of gSuboxone. Further, gCopaxone is delayed by one year, while USFDA approval to gAloxi, gPropofol and gNuvaring are expected in FY19-20E. The regulatory issues at its Miryalaguda and Bach...

    Reduce Reco. Price: 2,321.00

  • Pfizer

    Pfizer has only domestic operations, which faces less regulatory risk. Company has consistently delivered stable margins and healthy returns ratios. The debt free and cash rich (Q4FY18 cash per share at Rs387) balance sheet and high brand equity are the key...

    Reduce Reco. Price: 2,575.00

  • Jubilant Life

    We expect revenue/PAT CAGR of 18.6%/28.5% respectively over FY18-20E. The price erosion in the US market remains a challenge to its US generic business. In life science ingredients (LSI), company would transit to profitable products with better product mix....

    Buy Reco. Price: 735.00

  • Syngene Intl.

    Syngene is moving up in the CRO value chain by expanding its research capabilities and foraying in API manufacturing in FY20E. The new capabilities will help to expand client base, drive growth going forward. We expect 22.5% CAGR in the top-line and 27.4% C...

    Buy Reco. Price: 593.00

  • Biocon

    Biocon’s early entry in the biosimilars business is a long term positive for the company. Biocon-Mylan has recently received an approval for Trastuzumab and Pegfilgrastim in US and we expect approval to 3-4 more biosimilars in 2018/2019 across US and ...

    Buy Reco. Price: 620.00

  • Strides Shasun

    Strides Shasun has been restructuring its business and has exited its India business. Strides is also expected to derive synergies by merging its Australia business with Apotex, which will have ~50% market share of the local generics market. The Austral...

    Buy Reco. Price: 394.00

  • Aster DM Health.

    The company has doubled its hospital capacity in the past three years and has also reduced the dependence on governments for its hospital business in the GCC region. Company is adding total 423/307 more hospital beds in India/GCC over FY19-20E. Currently, A...

    Accumulate Reco. Price: 174.50

  • Kansai Nerolac

    KNPL has ~55:45 revenue mix from decorative and industrial paints respectively. KNPL is favourably positioned to benefit from IIP revival and increasing demand for housing. Its Q4FY18 results reflected pressure on operating margins due to rising crude p...

    Buy Reco. Price: 469.00

  • Piramal Enterp.

    After selling its domestic pharma business in 2010, Piramal Enterprises (PEL) has successfully diversified and grown its business. PEL’s loan book in financial services business is expected to grow at 47% CAGR over FY18-20E with healthy ROE. PEL is ta...

    Buy Reco. Price: 2,555.00